1
Home
Companies

Enanta Pharmaceuticals

#7483

Rank

$389.15M

Marketcap

US United States

Country

Enanta Pharmaceuticals
Leadership team

Dr. Jay R. Luly (Pres, CEO & Director)

Mr. Paul J. Mellett Jr. (Sr. VP of Fin. & Admin. and CFO)

Dr. Yat Sun Or Ph.D. (Sr. VP of R&D and Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Watertown, Massachusetts, United States
Established
1998
Company Registration
SEC CIK number: 0001177648
Revenue
20M - 100M
Traded as
ENTA
Social Media
URL
https://www.enanta.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
History

Enanta was founded in 1998 by scientists and venture capitalists who saw potential in the development of small molecule drugs. Since its inception, Enanta has been dedicated to researching, developing, and commercializing innovative treatments for viral diseases, liver diseases, and respiratory diseases.

Mission
At Enanta, our goal is to develop novel medicines to improve the outlook for patients with viral, liver, and respiratory diseases.
Vision
Enanta's vision is to become a leader in the life sciences, to bring forward the most effective medications for viral, liver, and respiratory diseases, and to become a provider of healthcare solutions to improve the lives of people around the globe.
Key Team

Ms. Tara Lynn Kieffer Ph.D. (Sr. VP of New Product Strategy & Devel.)

Mr. Brendan Luu (Sr. VP of Bus. Devel.)

Ms. Jennifer Viera (Sr. Director of Investor Relations & Corp. Communications)

Mr. Nathaniel S. Gardiner J.D. (Sr. VP, Gen. Counsel & Sec.)

Dr. Nathalie Adda M.D. (Consultant)

Dr. Scott T. Rottinghaus (Sr. VP & Chief Medical Officer)

Recognition and Awards
Enanta has been the recipient of numerous awards and recognitions, including the National Institutes of Health Director's Award and the Forbes Top 300 Best Small Companies Award. Enanta has also been recognized by The Boston Globe as one of the 100 Top Places to Work in Massachusetts.
References

https://in.investing.com/equities/enanta-pharmaceuticals-inc

https://finance.yahoo.com/quote/ENTA/profile?p=ENTA

https://www.crunchbase.com/organization/enanta-pharmaceuticals

https://sec.report/CIK/0001177648

https://companiesmarketcap.com/

https://www.enanta.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Enanta Pharmaceuticals
Leadership team

Dr. Jay R. Luly (Pres, CEO & Director)

Mr. Paul J. Mellett Jr. (Sr. VP of Fin. & Admin. and CFO)

Dr. Yat Sun Or Ph.D. (Sr. VP of R&D and Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Watertown, Massachusetts, United States
Established
1998
Company Registration
SEC CIK number: 0001177648
Revenue
20M - 100M
Traded as
ENTA
Social Media
URL
https://www.enanta.com